Document is current

Article History

Received: 14 August 2024

Accepted: 21 November 2024

First Online: 29 November 2024

Declarations

:

: The DANE study (NCT05373017, R01AG076489) received approval from the University of Wisconsin-Madison/University of Wisconsin Hospitals and Clinics Institutional Review Board (IRB, no. 2022–0545, approval date September 14, 2022), and Indiana University agreed to cede IRB review to University of Wisconsin-Madison/University of Wisconsin Hospital and Clinics (September 29, 2022). The approval included generating reports to the research team and the funding agency of which this dashboard was part.

: Not applicable.

: Dr. Boustani serves as a chief Scientific Officer and co-Founder of BlueAgilis; the Chief Health Officer of DigiCare Realized, Inc.; and the Chief Health Officer of Mozyne Health, Inc. He has equity interest in Blue Agilis, Inc; DigiCare Realized, Inc; and Mozyne Health Inc.; he sold his equity in Preferred Population Health Management LLC and MyShift, Inc. (previously known as RestUp, LLC). He serves as an advisory board member for Eli Lilly and Co, Eisai, Inc; Merck & Co Inc; Biogen Inc; and Genentech Inc. These conflicts have been reviewed by Indiana University and have been appropriately managed to maintain objectivity.